Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peptide transporter 1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Peptide transporter 1. Displaying page 1 of 1.
    EudraCT Number: 2016-003343-11 Sponsor Protocol Number: GLP1ALCOHOL Start Date*: 2017-04-12
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence?
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10001125 Addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001381-96 Sponsor Protocol Number: LG_T1_EGP Start Date*: 2014-06-17
    Sponsor Name:Medizinische Universität Graz / Endokrinologie und Stoffwechsel
    Full Title: A randomized, double blind, two-period cross-over trial investigating the effect of liraglutide as add on to intensive insulin treatment on the endogenous glucose production in subjects with C-pept...
    Medical condition: Diabetes Mellitus Type 1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001215-39 Sponsor Protocol Number: NN9828-4150 Start Date*: 2015-08-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investiga...
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) DK (Completed) FI (Completed) ES (Completed) IE (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004553-25 Sponsor Protocol Number: CCFZ533X2207 Start Date*: 2019-09-25
    Sponsor Name:Novartis Pharma AG
    Full Title: Investigator- and subject-blinded, randomized, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and efficacy of CFZ533 in pediatric and young adults with new onset type 1...
    Medical condition: Treatment of subjects with type 1 diabetes mellitus with residual beta cell function (RBCF), with the goal of preserving RBCF
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) SI (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018775-17 Sponsor Protocol Number: TRX4_DM_019_EU_10 Start Date*: 2010-07-02
    Sponsor Name:GlaxoSmithKline
    Full Title: DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) FI (Completed) GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004926-26 Sponsor Protocol Number: PRV-031-001 Start Date*: 2019-11-21
    Sponsor Name:Provention Bio, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in ...
    Medical condition: Type 1 Diabetes (T1D)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) FR (Completed) FI (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-022549-59 Sponsor Protocol Number: TRX4_DM_J20_GER_10 Start Date*: 2011-03-03
    Sponsor Name:Tolerx, Inc.
    Full Title: DEFEND 2A: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes in Adolescents
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002205-40 Sponsor Protocol Number: OTX115495 (DEFEND-1 EU) Start Date*: 2008-08-29
    Sponsor Name:Tolerx, Inc. [...]
    1. Tolerx, Inc.
    2. GlaxoSmithKline
    Full Title: DEFEND-1: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes
    Medical condition: Otelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are cu...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005878-10 Sponsor Protocol Number: ISIS757456-CS5 Start Date*: 2021-05-06
    Sponsor Name:Ionis Pharmaceuticals
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production, Ad...
    Medical condition: Chronic Heart Failure with Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003028-30 Sponsor Protocol Number: 808040019 Start Date*: 2015-11-02
    Sponsor Name:Technische Universität München, Fakultät für Medizin
    Full Title: Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes
    Medical condition: Risk for type 1 diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000669-21 Sponsor Protocol Number: 1218-0091 Start Date*: 2018-04-02
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
    Full Title: A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ...
    Medical condition: Diabetes Mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) Outside EU/EEA DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-001821-34 Sponsor Protocol Number: 200977 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) ES (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 17:54:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA